Introduction  

​

"There are a whole lot of individual practitioners, most of whom are not actually practitioners, who are there for financial gain,” observes Helena Teede, a leading PCOS researcher, in an interview with The Guardian. “The biggest challenge I have is the misinformation, and then associated with that, the harm that’s done by denigrating actual evidence-based strategies. Which, in the end, does a disservice to women with the condition” (Brinkhurst-Cuff). 

     For as long as women’s health has existed, it has been at the crossroads of medicine, profit, and neglect. From contraceptives to fertility treatments, the pharmaceutical paths offered to women often appear as a narrow passage where every door opens onto a compromise more damaging than the alternative. One striking example is polycystic ovary syndrome (PCOS), which illustrates this dilemma vividly. Affecting up to ten percent of reproductive-age women worldwide, PCOS is one of the most common endocrine disorders, with wide-ranging effects on metabolism, fertility, and mental health (Brinkhurst-Cuff). 

     Yet despite its prevalence, treatment options remain remarkably limited, centering on a handful of drugs that often manage symptoms at the cost of a plethora of complications that may last a lifetime. Women must either live with the consequences of untreated PCOS or accept pharmaceutical management accompanied by side effects that reshape their daily lives. 

     This reality raises a troubling ethical question: why, in a field as critical as gynecology, do pharmaceutical solutions for PCOS continue to present women with only two paths: untreated suffering or medically managed suffering? 

​

Background – The Complexity of PCOS 

​

     PCOS is not a single disease but a cluster of interconnected conditions, including irregular ovulation, excess androgen production, insulin resistance, obesity, and elevated risks for cardiovascular disease and diabetes. It is also associated with mental health burdens, such as depression, anxiety, and poor self-image, often driven by visible symptoms like acne, excess hair, and weight gain (“The Impact of PCOS on Women’s Mental Health”). 

     Despite its complexity, the clinical approach to PCOS has historically been reductionist. Rather than seeking treatments that address underlying mechanisms, the medical system often focuses on “managing” cycles or symptoms. This narrowness is not simply a clinical shortcoming; it reflects a deeper ethical issue in the medicalization of women’s health.

​

Pharmaceutical Paths: A Closer Look 

​

Insulin-Sensitizing Agents (Metformin)

Initially developed for type 2 diabetes, metformin is commonly prescribed for PCOS because it lowers insulin resistance. Evidence suggests it can improve ovulation rates and modestly increase live births, particularly when combined with other interventions (“Metformin”). However, side effects such as gastrointestinal distress, nausea, diarrhea, and abdominal pain are common, and rare but serious risks such as lactic acidosis cannot be overlooked. Ethically, metformin represents a trade-off: it offers incremental benefit while imposing daily discomfort, making many women question whether symptom management is worth the price. 

Hormonal Contraceptives and Cycle Regulation

Oral contraceptives and hormonal intrauterine devices are frequently the first-line treatment offered to women with PCOS (“Medications for PCOS”). These drugs regulate menstrual cycles, reduce acne, and help manage androgen-related symptoms. However, their benefits come at the cost of suppressing natural hormonal rhythms, raising questions about whether women are being “regulated” rather than restored. Many patients describe feeling dismissed when these options are presented as universal fixes. In practice, such drugs manage surface-level symptoms while leaving deeper metabolic dysfunction untouched. 

Anti-Androgens (Spironolactone)

Spironolactone is prescribed to reduce acne and excess hair by blocking androgen receptors. While effective cosmetically, it causes menstrual irregularities in up to seventy percent of women on high doses and requires strict contraception due to the risk of congenital disabilities if pregnancy occurs (“Spironolactone”). The paradox here is striking: a drug prescribed to address one symptom often destabilizes another essential function, forcing women into cycles of “side effect management” rather than holistic healing. 

Fertility Treatments: Clomiphene and Letrozole

For women with PCOS who want to conceive, fertility treatments introduce another layer of complexity. Clomiphene, a traditional ovulation-inducing drug, has been associated with lower success rates, mood disturbances, and a higher risk of multiple pregnancies. Letrozole, originally a breast cancer drug, has shown higher live birth rates with fewer multiples (“A Breast-Cancer Drug”). While letrozole represents an improvement, its very existence highlights a broader issue: progress in women’s reproductive health often depends on drugs borrowed from other fields rather than those developed with women’s needs at the forefront. Here, the paradox is evident: a drug prescribed to address one symptom often destabilizes another essential function, forcing women into a cycle of “side effect management” rather than holistic healing. I myself take multiple of these medications, in order to manage my symptoms, so I would have firsthand experience as to what these drugs and their side effects truly can affect someone in their day-to-day life. 

​

The Ethical Dimension – Autonomy and Medicalization 

​

     The ethical tension at the heart of PCOS treatment lies in autonomy. According to the British Medical Association, autonomy is defined as “the right of adults with capacity to make informed decisions about their own medical care” (“Autonomy or Self-Determination”). However, how autonomous can decisions be when patients are offered only narrow, pharmaceutical-driven paths?

     The medicalization of PCOS, framing it as a problem to be controlled by pills, reduces the condition to symptoms while obscuring its broader psychosocial impacts. It also reinforces a troubling historical pattern in women’s health: treatments designed to silence or regulate the body, rather than listen to it. 

 

The Human Cost – A Personal Perspective 

 

     As someone who has personally navigated PCOS, I have felt this double bind. Doctors offered me metformin for insulin resistance and contraceptives for my irregular cycles. I took the pills, and some symptoms eased, but the trade-offs were relentless: nausea, fatigue, and mood swings. I often felt like I was choosing between two kinds of suffering, the visible suffering of unmanaged PCOS or the quiet, internal suffering of side effects. 

     Perhaps what struck me most was the lack of conversation. Rarely did providers ask how I felt about these trade-offs or whether the side effects were compromising my daily life. The treatment paradigm seemed fixed: one drug for one symptom, regardless of the toll. I began to wonder whether women with PCOS are being offered actual treatment or merely containment. 

 

Beyond Pharmaceuticals – The Role of Lifestyle and Evidence-Based Care 

 

     International guidelines increasingly acknowledge what patients have long known: lifestyle interventions such as diet, exercise, and stress reduction are foundational in PCOS management. They are often more effective than drugs alone (Teede et al.). Mental health support is also critical, given the elevated risks of depression and anxiety. However, in clinical practice, these holistic approaches are frequently overshadowed by the convenience of prescriptions. This imbalance reflects both systemic inertia and pharmaceutical influence. As Teede warns, oversimplified solutions and misinformation, often perpetuated online, leave patients overwhelmed and underserved (Brinkhurst-Cuff). 

 

Broader Implications – What PCOS Reveals About Women’s Health 

 

     The constrained pharmaceutical landscape of PCOS is not an isolated issue. It is emblematic of women’s health more broadly, where treatments are often reactive rather than preventive, suppressive rather than restorative. McKinsey & Company reports that “female-only conditions account for just 4 percent of pharmaceutical pipelines” (Closing the Women’s Health Gap). That number is striking when you consider that conditions like PCOS, endometriosis, and menopause collectively affect hundreds of millions of women worldwide. 

     For me, this statistic is more than abstract. When I look back on my own PCOS journey, I see exactly what this lack of investment produces: a handful of recycled drugs borrowed from diabetes, oncology, or dermatology, each carrying its own burdens. It explains why I was told repeatedly to “just take birth control” as though my entire condition could be compressed into a regulated cycle. It explains why the side effects of metformin were brushed off as tolerable trade-offs. In other words, that “4 percent” is not just a number, but it is the reason patients like me often feel invisible in the pharmaceutical system.

     This gap forces women into a double bind. We either accept the limited options available and manage a cascade of side effects, or we try to navigate life without treatment, bearing the risks and symptoms on our own. Both paths are products of an industry that has not prioritized female-specific conditions in proportion to their prevalence or impact. PCOS, then, is not an isolated oversight but a window into a much larger neglect within women’s health research. 

      If women make up half the population, why is their health still treated as an afterthought in the pharmaceutical pipeline? 

 

Conclusion – Reimagining Care 

 

     PCOS patients deserve more than symptom management and difficult trade-offs. They deserve treatments that respect autonomy, address root causes, and recognize the holistic nature of health. This means reimagining gynecological care to integrate pharmaceuticals with lifestyle interventions, mental health support, and transparent communication. 

     I am ashamed not only of how long it took for me to be diagnosed, but also of how little support I received afterward. Too often my concerns were dismissed as lifestyle issues, and even after diagnosis I found myself lost in a sea of unanswered questions. Although I am not a healthcare professional, I still hope to make an impact for the growing community of women with PCOS. My hope is that awareness spreads so women are informed before diagnosis and supported afterward. 

     Until then, women with PCOS—and, by extension, women navigating countless other reproductive health issues—will continue to face the same constrained choice: cure or complication. The challenge for medicine is not only to expand the range of options but to ask a deeper question: why has women’s health been narrowed to so few paths in the first place?